Number of items: 4.
2023
Yeoh, S. E. et al.
(2023)
Dapagliflozin versus metolazone in heart failure resistant to loop diuretics.
European Heart Journal, 44(31),
pp. 2966-2977.
(doi: 10.1093/eurheartj/ehad341)
(PMID:37210742)
Yeoh, S. E. et al.
(2023)
Endothelin-1, outcomes in patients with heart failure and reduced ejection fraction, and effects of dapagliflozin: findings from DAPA-HF.
Circulation, 147(22),
pp. 1670-1683.
(doi: 10.1161/CIRCULATIONAHA.122.063327)
(PMID:37039015)
(PMCID:PMC10212584)
2022
Yeoh, S. E. et al.
(2022)
Relationship of dapagliflozin with serum sodium: findings from the DAPA-HF trial.
JACC: Heart Failure, 10(5),
pp. 306-318.
(doi: 10.1016/j.jchf.2022.01.019)
(PMID:35483792)
Yeoh, S. E., Dewan, P. , Serenelli, M., Ferreira, J. P., Pitt, B., Swedberg, K., Veldhuisen, D. J., Zannad, F., Jhund, P. S. and McMurray, J. J.V.
(2022)
Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES.
European Journal of Heart Failure, 24(3),
pp. 529-538.
(doi: 10.1002/ejhf.2350)
(PMID:34536265)
(PMCID:PMC10654446)
This list was generated on Sat Nov 9 23:03:57 2024 GMT.